Advancing the Development of Imsidolimab with AnaptysBio

We are excited to share some good news! Congratulations AnaptysBio on the orphan drug designation of imsidolimab for the treatment of GPP! We are thrilled to manage this clinical trial and help advance the development of imsidolimab.

 

For more information on our services, visit https://innovaderm.com/full-service-dermatology-cro/

 

About Anaptys:

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

Contact us

Newsletter

Get notified to have the latest trends and be at the forefront of dermatology clinical research and innovation.

Newsletter subscription resources

*By subscribing to our newsletter, you acknowledge and agree to the terms of our privacy policy.